Form 8-K - Current report:
SEC Accession No. 0000950170-24-113963
Filing Date
2024-10-10
Accepted
2024-10-10 08:42:12
Documents
12
Period of Report
2024-10-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20241010.htm   iXBRL 8-K 40411
2 EX-99.1 kzr-ex99_1.htm EX-99.1 8925
  Complete submission text file 0000950170-24-113963.txt   162008

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20241010.xsd EX-101.SCH 23931
14 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20241010_htm.xml XML 4536
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

EIN.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 241363887
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)